ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes by Jessica W. Chen, William Jacot, Javier Cortés, Ian E. Krop, Susan Dent, Nadia Harbeck, Michelino De Laurentiis, Véronique Diéras, Young‐Hyuck Im, Thomas J. Stout, Frauke Schimmoller, Heidi M. Savage, Katherine E. Hutchinson, Timothy R. Wilson

Get full text

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

Get full text

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients by Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P. Kelly Marcom, Lowell L. Hart, John W. Smith, Karen L. Tedesco, Eitan Amir, Ian E. Krop, Angela M. DeMichele, Pamela J. Goodwin, Margaret Block, Kimberly Aung, Martha E. Brown, Robert T. McCormack, Daniel F. Hayes

Get full text

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer by Michalina Janiszewska, Shayna Stein, Otto Metzger Filho, Jennifer Eng, Natalie L. Kingston, Nicholas W. Harper, Inga H. Rye, Maša Alečković, Anne Trinh, Katherine C. Murphy, Elisabetta Marangoni, Simona Cristea, Benjamin Oakes, Eric P. Winer, Ian E. Krop, Hege G. Russnes, Paul T. Spellman, Elmar Bucher, Zhi Hu, Koei Chin, Joe W. Gray, Franziska Michor, Kornelia Polyak

Get full text

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer by Adrienne G. Waks, Neelam V. Desai, Tianyu Li, Philip D. Poorvu, Ann H. Partridge, Natalie Sinclair, Laura M. Spring, Meredith Faggen, Michael Constantine, Otto Metzger, Jillian Alberti, Julia Deane, Shoshana M. Rosenberg, Elizabeth Frank, Sara M. Tolaney, Ian E. Krop, Nadine M. Tung, Nabihah Tayob, Tari A. King, Elizabeth A. Mittendorf, Eric P. Winer

Get full text

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials by Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou

Get full text

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer by Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon

Get full text

TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer by Filipa Lynce, Laura E. Stevens, Zheqi Li, Jane E. Brock, Anushree Gulvady, Ying Huang, Faina Nakhlis, Ashka Patel, Jeremy M. Force, Tufia C. Haddad, Naoto Ueno, Vered Stearns, Antonio C. Wolff, Amy S. Clark, Jennifer R. Bellon, Edward T. Richardson, Justin M. Balko, Ian E. Krop, Eric P. Winer, Paulina Lange, E. Shelley Hwang, Tari A. King, Sara M. Tolaney, Alastair Thompson, Gaorav P. Gupta, Elizabeth A. Mittendorf, Meredith M. Regan, Beth Overmoyer, Kornelia Polyak

Get full text

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. by Michael J Kluk, Todd Ashworth, Hongfang Wang, Birgit Knoechel, Emily F Mason, Elizabeth A Morgan, David Dorfman, Geraldine Pinkus, Oliver Weigert, Jason L Hornick, Lucian R Chirieac, Michelle Hirsch, David J Oh, Andrew P South, Irene M Leigh, Celine Pourreyron, Andrew J Cassidy, Daniel J Deangelo, David M Weinstock, Ian E Krop, Deborah Dillon, Jane E Brock, Alexander J F Lazar, Myron Peto, Raymond J Cho, Alexander Stoeck, Brian B Haines, Sriram Sathayanrayanan, Scott Rodig, Jon C Aster

Get full text

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036 by Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, J. Felix Olivares-Quintero, Michael P. East, Maki Tanioka, Jon S. Zawistowski, Darshan Singh, Noah Sciaky, Xin Chen, Xiaping He, Naim U. Rashid, Lynn Chollet-Hinton, Cheng Fan, Matthew G. Soloway, Patricia A. Spears, Stuart Jefferys, Joel S. Parker, Kristalyn K. Gallagher, Andres Forero-Torres, Ian E. Krop, Alastair M. Thompson, Rashmi Murthy, Michael L. Gatza, Charles M. Perou, H. Shelton Earp, Lisa A. Carey, Gary L. Johnson

Get full text